Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Stephen N Davis, Jennifer M Perkins

Abstract

To review the role of the endogenous cannabinoid system (ECS) in the peripheral and central regulation of food intake, appetite, and energy storage and discuss the potential for the ECS to be an important target for lowering cardiovascular risk. Materials used for this article were identified through a MEDLINE search of the pertinent literature (1975 to present), including English-language randomized controlled, prospective, cohort, review, and observational studies. We summarize the available experimental and clinical data. The ECS is composed of two 7-transmembrane G protein-coupled cannabinoid receptor subtypes, CB1 and CB2, endogenous cannabinoid ligands (anandamide and 2-arachidonoylglycerol), and the enzymes that synthesize and break down the ligands. Understanding the role of the ECS in central and peripheral metabolic processes related to the regulation of food intake and energy balance as well as the endocrine role of excess adipose tissue, particularly visceral adipose tissue, and its promotion of global cardiometabolic risk has led to the development of pharmacologic agents with potential for blockade of CB1 receptors. In several studies, rimonabant (20 mg daily) demonstrated a favorable effect on various risk factor...Continue Reading

References

Jan 22, 1993·The Journal of Comparative Neurology·L A MatsudaS J Lolait
Jan 1, 1996·Neuroscience and Biobehavioral Reviews·K C Berridge
Jul 1, 1997·Journal of Neurophysiology·W TwitchellK Mackie
Jan 1, 1997·Pharmacology & Therapeutics·R G Pertwee
Dec 10, 1998·JAMA : the Journal of the American Medical Association·K M RexrodeJ E Manson
Jan 12, 1999·British Journal of Pharmacology·T CrociG Ferla
Apr 15, 2000·Nature·M W SchwartzD G Baskin
Sep 21, 2000·Trends in Endocrinology and Metabolism : TEM·R S Ahima, J S Flier
Sep 21, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·G GiacchettiF Mantero
Nov 1, 2000·Nature·M TschöpM L Heiman
Mar 16, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·G Boden
Mar 27, 2001·BMJ : British Medical Journal·J P DesprésD Prud'homme
May 10, 2001·The Journal of Clinical Endocrinology and Metabolism·C WeyerP A Tataranni
Jul 27, 2001·Diabetes·G MarchesiniN Melchionda
Sep 22, 2001·Hypertension·F F Ribeiro-FilhoS R Ferreira
Oct 27, 2001·Diabetes·A M WrenS R Bloom
Nov 8, 2001·Trends in Pharmacological Sciences·E Schlicker, M Kathmann

❮ Previous
Next ❯

Citations

Feb 25, 2009·Diabetes, Obesity & Metabolism·Souzana ChousseinStella S Daskalopoulou

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.